- Home
- Research
- Endocannabinoid
- A photoswitchable ligand for opposite control over cannabinoid receptors CB1 and CB2.
Light lets one molecule switch CB1 on and CB2 off
A photoswitchable ligand for opposite control over cannabinoid receptors CB1 and CB2.
AI Summary
Researchers developed Azo23, a light-sensitive molecule designed to control the two main cannabinoid receptors, CB1 and CB2. Ultraviolet light changes Azo23 from its trans form to its cis form, switching how it interacts with these receptors. After irradiation, the molecule acts as a potent CB1 agonist while blocking CB2 activity as an antagonist.
The compound showed an activity shift of more than 50-fold, and molecular modeling suggested that different interactions with each receptor explain its opposing effects. This is a laboratory research tool rather than a cannabis product or treatment, but it could help scientists separate the often-overlapping roles of CB1 and CB2. In the longer term, light-controlled compounds such as Azo23 may support more precise investigation of cannabinoid signaling, although the abstract does not report testing in people or practical effects for cannabis users.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Review links cannabis to possible heart attack mechanisms, not proven risk
Visceral fat endocannabinoid production rose with diabetes, not obesity alone
Targeted CB2 drug delivery reduced mouse plaque deposits, with sex differences
Explore More Research
Stay informed about the latest cannabis science.